Could Some Cancer Drugs Protect Against COVID-19?

A new study suggests that certain cancer drugs that lower levels of a receptor called angiotensin-converting enzyme 2 (ACE2), which is found on the surface of human cells and allows the coronavirus to attach, may provide some protection against COVID-19 infection.
These cancer drugs include TOR/PI3K inhibitors (everolimus, temsirolimus and alpelisib), antimetabolites (decitabine and gemcitabine), mitotic inhibitors (cabazitaxel) and other kinase inhibitors (dasatinib and crizotinib).
The study, conducted at Memorial Sloane Kettering Center (MSKCC) in New York City between March 10 and May 28, 2020, during the early months of the COVID-19 pandemic, included 1701 patients receiving cancer treatment.
The researchers found that patients treated with cancer drugs that lower ACE2 levels had a significantly lower rate of SARS-CoV-2 test positivity than patients receiving other drugs (7% versus 12.9%).
Study author Michael Foote, a research fellow at MSKCC, said of the study: “Many oncologists worry that treating patients with certain cancer drugs may increase their risk of COVID-19. Because of this paper, some oncologists may feel a little more comfortable treating a patient with a particular drug on our list during the pandemic.”
He also suggested that the findings could stimulate new research. There is considerable interest in discovering new molecular signaling patterns that the virus uses to survive and multiply. A reduction in viruses' ability to enter cells with certain compounds suggests that they may disrupt the specific signaling pathways SARS-CoV-2 needs to replicate. Further research could explore these new viral signaling pathways in a laboratory to better understand how the virus multiplies and potentially design new antiviral drugs for all patients, not just those with cancer.
The study was published online on August 19 in JAMA Oncology.
In the first part of their study, the team used computer simulation to identify cancer drugs associated with reduced ACE2 gene expression. They then evaluated patients receiving these drugs during the pandemic.
Of the 1701 study participants, 215 (12.6%) received an ACE2-lowering cancer drug.
Gemcitabine chemotherapy in particular was associated with reduced SARS-CoV-2 positivity (odds ratio 0.42).
It should be remembered that this study was a retrospective analysis, rather than a randomized controlled clinical trial. Randomized controlled clinical trials are the gold standard for determining whether a drug works for a patient.
These findings also come from very early in the pandemic, before COVID-19 vaccines were available. This study may be meaningful because it evaluated some drugs' effects on the virus before vaccination.
However, with effective vaccines now available, it is unclear how these findings should be applied. We certainly know that vaccines are the most effective way to prevent viral spread. The delta variant has been shown to have a particularly strong interaction between the virus and the ACE2 receptor; whether the cancer drugs would be more or less effective against this variant is unknown.
*
RELATED TOPICS
- Covid-19: Current Statistics for the World and Turkey
- Latest News and Scientific Developments on Coronavirus
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.